Drug assessment at a glance: A25-153[1]

Lisocabtagene maraleucel (mantle cell lymphoma)

20 July 2026

[1] This is a courtesy translation of the summary provided as a service by IQWiG. For further information on the subject matter and the result of the assessment, please refer to the dossier assessment for Project A25-153. The G-BA decides on the added benefit.

Research question for the benefit assessment

Population	Adult patients with relapsed or refractory mantle cell lymphoma after at least 2 lines of systemic therapy including a BTK inhibitor
Intervention	lisocabtagene maraleucel
Comparator	Individualized treatment from a choice of ▪ bendamustine + rituximab, ▪ lenalidomide ± rituximab, ▪ R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone), ▪ VRCAP (bortezomib, rituximab, cyclophosphamide, doxorubicin, prednisone), ▪ R-BAC (rituximab + bendamustine + cytarabine), ▪ R-FCM (fludarabine + cyclophosphamide + mitoxantrone + rituximab), ▪ ibrutinib, ▪ temsirolimus, ▪ brexucabtagene autoleucel, ▪ venetoclax, ▪ high-dose therapy with allogeneic stem cell transplantation, and ▪ high-dose therapy with autologous stem cell transplantation
Outcomes	At least one patient-relevant outcome

Overview of positive and negative effects

	Size of the effects		Informative value of the effects	
Mortality	∅		–	
Morbidity	∅		–	
Symptoms	∅		–	
Health-related quality of life	∅		–	
Side effects	∅		–	
	∅	No (suitable) data	–	Not applicable
	↔	No advantage or disadvantage	★	Low
	↑ / ↓	Small advantage/disadvantage	★★	Moderate
	↑↑ / ↓↓	Moderate advantage/disadvantage	★★★	High
	↑↑↑ / ↓↓↓	Large advantage/disadvantage		

Overall: No advantage or disadvantage (no suitable data)

Evidence base and noteworthy aspects

- No suitable data were available.

- The single-arm TRANSCEND-NHL-001 study did not allow for a comparison with the comparator therapy.
- Regarding study CA0821138, the study pool on the comparator side was potentially incomplete. Notwithstanding this, MAIC analyses without a common comparator are not an adequate option for confounder adjustment.

References

Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Lisocabtagen maraleucel (Mantelzell-Lymphom); Nutzenbewertung gemäß § 35a SGB V; Dossierbewertung [online]. 2026 [Accessed: 13.04.2026]. URL: https://doi.org/10.60584/A25-153.

Gemeinsamer Bundesausschuss. Nutzenbewertungsverfahren zum Wirkstoff Lisocabtagen maraleucel (Neues Anwendungsgebiet: Mantelzell-Lymphom, nach ≥ 2 Vortherapien) [online]. 2026 [Accessed: 13.04.2026]. URL: https://www.g-ba.de/bewertungsverfahren/nutzenbewertung/1295/.

English translations for this project are published at https://www.iqwig.de/en/projects/a25-153.html.

Publisher details

Publisher

Institute for Quality and Efficiency in Health Care (IQWiG)

Address

Siegburger Str. 237
50679 Köln
Germany

Phone: +49 221 35685-0
Fax: +49 221 35685-1
Email: info@iqwig.de
Internet: www.iqwig.de